Bio Sequence

Biological Glossary | What is Chemical Modification?

9 November 2023
2 min read

Chemical modifications in biology refer to the changes in biomolecular structure and function brought about by the addition or removal of modifying elements. This process, often done through a series of chemical reactions, can be applied to any macromolecule including proteins, nucleic acids, carbohydrates, and lipids. Chemical modifications are significant for their potential to enhance the stability of biomolecules, aiding the organism in managing physiological stressors, and in drug development for various diseases. Common chemical modifications include processes like phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, acetylation, lipidation, and proteolysis. Each of these modifications can work individually or collectively. The ongoing study of chemical modifications is due to the wide range of possible modifications that can introduce variability into the proteome.

Free registration is available for the Bio biological sequence database: https://bio-patsnap-com.libproxy1.nus.edu.sg. Act now to expedite your sequence search tasks.

图片包含 图示

描述已自动生成

IDRx shares initial findings from its ongoing Phase 1 StrateGIST trial at CTOS 2023, illustrating the promise of IDRX-42 for GIST patients
Latest Hotspot
3 min read
IDRx shares initial findings from its ongoing Phase 1 StrateGIST trial at CTOS 2023, illustrating the promise of IDRX-42 for GIST patients
9 November 2023
IDRx, Inc. has reported initial clinical results from its ongoing Phase 1 StrateGIST trial of IDRX-42. This trial is for patients with metastatic and/or inoperable gastrointestinal stromal tumors who have previously received at least one tyrosine kinase inhibitor therapy regime, now testing a higher dosage.
Read →
Research, Patent, and Literature Data behind the Early ADC Drug ORM-6151 Purchased by Bristol-Myers Squibb at a Huge Cost
Bio Sequence
3 min read
Research, Patent, and Literature Data behind the Early ADC Drug ORM-6151 Purchased by Bristol-Myers Squibb at a Huge Cost
9 November 2023
ORM-6151 is a monoclonal antibody drug that targets CD33 and GSPT1, developed by Orum Therapeutics.
Read →
Fresenius Kabi introduces Tyenne*, the inaugural EU-sanctioned tocilizumab biosimilar
Latest Hotspot
3 min read
Fresenius Kabi introduces Tyenne*, the inaugural EU-sanctioned tocilizumab biosimilar
9 November 2023
Fresenius Kabi made an announcement about the introduction of Tyenne®, its tocilizumab biosimilar which references the RoActemra® (tocilizumab) in the European Union.
Read →
Satralizumab Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Satralizumab Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
20 November 2023
This article summarized the latest R&D progress of Satralizumab, the Mechanism of Action for Satralizumab, and the drug target R&D trends for Satralizumab.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.